Latest From Menarini Group
Will regulators in the EU follow their US counterparts in requiring more efficacy data for Daiichi Sankyo’s acute myeloid leukemia drug quizartinib, which is already approved in Japan?
Lucia and Giovanni Aleotti have been cleared of fraud against the Italian health system, and will continue to lead the Florentine company transformed into a major multinational by their father.
German Diabetes Stakeholders Like The New Talk On Strategy And Reimbursement, But Where's The Action?
The up-to-10 million diabetics in Germany could benefit from a more optimal combination of digital tools and conventional case to maintain glucose control, say local IVD companies. But the industry is still waiting on the promised National Diabetes Strategy, while the government talks about more reimbursement support for innovation.
The two firms hope improvement in the six-minute walk test might be accepted by the US FDA as registrational endpoint for reldesemtiv in spinal muscular atrophy. Blackstone acquires Clarus, while Merck licenses TriNKETs from Dragonfly.
In Vitro Diagnostics
- Chemistry, Immunoassay
- Glucose Testing
- Hematology, Coagulation
- Urine-based Testing
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Menarini Group
- Senior Management
Elcin Barker Ergrun, CEO
Stefano Pieri, Corp. Dir., Licensing & Bus. Dev.
- Contact Info
Phone: (39) 55 56 80 1
Via Dei Sette Santi 1/3
Florence , 50131
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.